- H.C. Wainwright raised the price target on Outlook Therapeutics Inc OTLK to $6 from $5 and reiterated a Buy rating.
- The Company announced "exceptionally strong" data that showed Lytenava's statistically significant superiority over Lucentis, analyst Douglas Tsao tells investors in a research note.
- he sees the 18% difference in the response rate as "leaving no doubt about Lytenava's performance." Tsao raised the drug's probability of success in wet macular degeneration to 80%.
- Early Tuesday, Lytenava aced the late-stage trial with a proportion of patients who gain at least 15 letters in the best-corrected visual acuity at 11 months.
- Price Action: OTLK shares are up 8.19% at $2.45 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
